ArticleAntimicrobial agents and chemotherapy2017
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 83 citations in OpenAlex.
- Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent.Pharmacology research & perspectives · 2021Trial
- Pharmacological advances inJournal of enzyme inhibition and medicinal chemistry · 2026Review
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- Multicenter surveillance of antifungal susceptibility of clinicalMicrobiology spectrum · 2026Article
- Invasive aspergillosis in lung and heart transplant recipients.JHLT open · 2026Article
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- Emerging Applications of Triazole Antifungal Drugs.International journal of molecular sciences · 2026Review
- StudyingPharmaceuticals (Basel, Switzerland) · 2025Review
- In vitro and clinical data demonstrate negligible risk of drug-drug interactions with opelconazole, a novel inhaled antifungal agent.The Journal of antimicrobial chemotherapy · 2025Article
- Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Innovative antifungal strategies to combat drug-resistantFrontiers in cellular and infection microbiology · 2025Review
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Fungal lung disease.The European respiratory journal · 2024Review
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- Accelerating the understanding ofCurrent research in microbial sciences · 2024Review
- An update on the global treatment of invasive fungal infections.Future microbiology · 2023Review
- Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections.Journal of fungi (Basel, Switzerland) · 2023Review
- Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health.ACS bio & med chem Au · 2023Review
- Antifungal chemotherapies and immunotherapies for the future.Parasite immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The profile of PC945, a novel triazole antifungal designed for administration via inhalation, was assessed in a range of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.